The prevalence of multiple sclerosis in 3 US communities

Curtis W Noonan, Dhelia M Williamson, Judy P Henry, Robert Indian, Sharon G Lynch, John S Neuberger, Randolph Schiffer, Janine Trottier, Laurie Wagner, Ruth Ann Marrie, Curtis W Noonan, Dhelia M Williamson, Judy P Henry, Robert Indian, Sharon G Lynch, John S Neuberger, Randolph Schiffer, Janine Trottier, Laurie Wagner, Ruth Ann Marrie

Abstract

Introduction: We estimated the prevalence of multiple sclerosis (MS) in 3 large geographic areas in the southern, middle, and northern United States.

Methods: The primary data source was medical records from office visits to private neurologists' practices or to neurology departments in tertiary care facilities during a 3-year period. Additional data sources included patient advocacy groups, nursing homes, and general practitioners.

Results: Three-year US age-adjusted prevalence estimates for the study areas varied substantially. The prevalence was lowest (47.2 per 100,000 population) in the Texas study area (33 degrees 30' north latitude), intermediate (86.3 per 100,000 population) in the Missouri study area (39 degrees 07' north latitude), and highest (109.5 per 100,000 population) in the Ohio study area (41 degrees 24' north latitude). The geographic differences remained strong after age-adjustment to the world standard population. The inverse association between UV light exposure and MS prevalence estimates was consistent with this observed latitude gradient. In all 3 areas, MS prevalence was highest among women, people aged 40 to 59 years, and non-Hispanics.

Conclusion: These results provide necessary prevalence estimates for community cluster investigations and establish baseline estimates for future studies to evaluate temporal trends in disease prevalence.

References

    1. Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology. 1994;13(1-2):1–7.
    1. Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin. 1996;14(2):291–308.
    1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–911.
    1. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133–146.
    1. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, et al. Primary progressive multiple sclerosis. Brain. 1997;120(Pt 6):1085–1096.
    1. Baum HM, Rothschild BB. The incidence and prevalence of reported multiple sclerosis. Ann Neurol. 1981;10(5):420–428.
    1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31(3):333–336.
    1. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology. 2002;58(1):136–138.
    1. Williamson DM, Henry JP. Challenges in addressing community concerns regarding clusters of multiple sclerosis and potential environmental exposures. Neuroepidemiology. 2004;23(5):211–216.
    1. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology. 2003;61(10):1373–1377.
    1. Multiple sclerosis among Lorain County, Ohio, residents 1998-2000. Atlanta (GA): Agency for Toxic Substances and Disease Registry; 2005.
    1. Multiple sclerosis prevalence: Independence and Sugar Creek, Missouri. Atlanta (GA): Agency for Toxic Substances and Disease Registry; 2004.
    1. Multiple sclerosis pilot surveillance: 19 Texas counties. Atlanta (GA): Agency for Toxic Substances and Disease Registry; 2004.
    1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–231.
    1. Freedman DM, Dosemeci M, Alavanja MC. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med. 2000;57(6):418–421.
    1. van der, Mei, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology. 2001;20(3):168–174.
    1. National Weather Service. UV index: annual time series. 2004.
    1. Zivadinov R, Iona L, Monti-Bragadin L, Bosco A, Jurjevic A, Taus C, et al. The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study. Neuroepidemiology. 2003;22(1):65–74.
    1. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected US population. Healthy People 2010 Stat Notes 2001;20:1–10.
    1. Hernan MA, Olek MJ, Ascherio A. A. Geographic variation of MS incidence in 2 prospective studies of US women. Neurology. 1999;53(8):1711–1718.
    1. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001;22(2):117–139.
    1. Enstrom JE, Operskalski EA. Multiple sclerosis among Spanish-surnamed Californians. Neurology. 1978;28(5):434–438.
    1. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol. 2004;55(1):65–71.
    1. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71(2):129–135.
    1. McGuigan C, Dunne C, Crowley J, Hagan R, Rooney G, Lawlor E, et al. Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland. J Neurol. 2005;252(10):1245–1248.
    1. Ebers GC, Sadovnick AD. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology. 1993;12(1):1–5.
    1. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol. 2007;61(6):504–513.
    1. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288–299.
    1. Nelson LM, Hamman RF, Thompson DS, Baum HM, Boteler DL, Burks JS, et al. Higher than expected prevalence of multiple sclerosis in northern Colorado: dependence on methodologic issues. Neuroepidemiology. 1986;5(1):17–28.
    1. Turabelidze G, Schootman M, Zhu BP, Malone JL, Horowitz S, Weidinger J, et al. Multiple sclerosis prevalence and possible lead exposure. J Neurol Sci. 2008;269(1-2):158–162.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する